Our results predict that: (1) inhibitors of hERG/KCNQ1 channels (Nakaya et al., 2000); (2) activators of Ca channel; or (3) cellular mediators that either limit IKr/IKs channel opening or promote ICa,L opening would be expected to limit abbreviation of atrial APD and therefore vulnerability to supraventricular arrhythmias in patients with metabolic disorders. The gene discussed is KCNQ1; the disease is metabolic disease.